Biomarkers and in vitro strategies for nephrotoxicity and renal disease assessment
Main Author: | |
---|---|
Publication Date: | 2020 |
Other Authors: | , , , , , |
Format: | Article |
Language: | eng |
Source: | Repositório Institucional da UFMG |
Download full: | https://doi.org/10.15761/NRD.1000162 http://hdl.handle.net/1843/52552 |
Summary: | Acute kidney injury (AKI) is a global public health concern, impacting nearly 13.3 million patients and resulting in three million deaths per year. Chronic Kidney Disease (CKD) has increased by 135% since 1990, representing the pathology with the fastest growth rate worldwide. The annual costs of dialysis and kidney transplants range between US$35,000 and US$100,000 per patient. Despite its great impact, kidney disease has remained mostly asymptomatic for many years. AKI continues to be a major, unmet medical condition for which there are no pharmacological treatments available, while animal models are limited to provide direction for therapeutic translation into humans. Currently, serum creatinine is the standard biomarker to identify nephrotoxicity; however, it is a late stage biomarker. Hence, there is a pressing need to study in vitro biomarkers for the assessment of nephrotoxicity in order to develop new and safer drugs. Understanding of the mechanisms by which molecules produce nephrotoxicity is vital in order to both prevent adversity and treat kidney injury. In this review, we address new technologies and models that may be used to identify earlier biomarkers and pathways involved in nephrotoxicity, such as cell culture, omic approaches, bioinformatics platform, CRISPR/Cas9 genome-editing, in silico, organoids and 3D bioprinting, considering adverse outcome pathways (AOP). |
id |
UFMG_7b94c5a1bb73e6f3ec6f0e5f97b79826 |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/52552 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
2023-04-26T21:36:50Z2023-04-26T21:36:50Z2020-0551114https://doi.org/10.15761/NRD.10001622399-908Xhttp://hdl.handle.net/1843/52552Acute kidney injury (AKI) is a global public health concern, impacting nearly 13.3 million patients and resulting in three million deaths per year. Chronic Kidney Disease (CKD) has increased by 135% since 1990, representing the pathology with the fastest growth rate worldwide. The annual costs of dialysis and kidney transplants range between US$35,000 and US$100,000 per patient. Despite its great impact, kidney disease has remained mostly asymptomatic for many years. AKI continues to be a major, unmet medical condition for which there are no pharmacological treatments available, while animal models are limited to provide direction for therapeutic translation into humans. Currently, serum creatinine is the standard biomarker to identify nephrotoxicity; however, it is a late stage biomarker. Hence, there is a pressing need to study in vitro biomarkers for the assessment of nephrotoxicity in order to develop new and safer drugs. Understanding of the mechanisms by which molecules produce nephrotoxicity is vital in order to both prevent adversity and treat kidney injury. In this review, we address new technologies and models that may be used to identify earlier biomarkers and pathways involved in nephrotoxicity, such as cell culture, omic approaches, bioinformatics platform, CRISPR/Cas9 genome-editing, in silico, organoids and 3D bioprinting, considering adverse outcome pathways (AOP).A lesão renal aguda (LRA) é um problema de saúde pública global, afetando cerca de 13,3 milhões de pacientes e resultando em três milhões de mortes por ano. A Doença Renal Crônica (DRC) aumentou 135% desde 1990, representando a patologia com maior taxa de crescimento em todo o mundo. Os custos anuais de diálise e transplante renal variam entre US$ 35.000 e US$ 100.000 por paciente. Apesar de seu grande impacto, a doença renal permaneceu assintomática por muitos anos. AKI continua a ser uma condição médica importante e não atendida para a qual não há tratamentos farmacológicos disponíveis, enquanto os modelos animais são limitados para fornecer orientação para tradução terapêutica em humanos. Atualmente, a creatinina sérica é o biomarcador padrão para identificar a nefrotoxicidade; no entanto, é um biomarcador de estágio tardio. Assim, há uma necessidade premente de estudar biomarcadores in vitro para a avaliação da nefrotoxicidade, a fim de desenvolver novas drogas mais seguras. A compreensão dos mecanismos pelos quais as moléculas produzem nefrotoxicidade é vital para prevenir adversidades e tratar lesões renais. Nesta revisão, abordamos novas tecnologias e modelos que podem ser usados para identificar biomarcadores precoces e vias envolvidas na nefrotoxicidade, como cultura de células, abordagens ômicas, plataforma de bioinformática, edição de genoma CRISPR/Cas9, in silico, organoides e bioimpressão 3D, considerando as vias de resultado adverso (AOP).CNPq - Conselho Nacional de Desenvolvimento Científico e TecnológicoFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas GeraisCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorengUniversidade Federal de Minas GeraisUFMGBrasilFAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICASICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIANephrology and Renal DiseasesInjúria renal agudaInsuficiência renal crônicaRotas de resultados adversosDiagnóstico precoceNefrologiaAcute kidney injury (AKI)Adverse outcome pathways (AOP)Chronic kidney disease (CKD)Early diagnosisNephrotoxicity modelsNew technologiesBiomarkers and in vitro strategies for nephrotoxicity and renal disease assessmentinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://www.oatext.com/biomarkers-and-in-vitro-strategies-for-nephrotoxicity-and-renal-disease-assessment.phpStellamaris SoaresLarissa Camila Ribeiro de SouzaMark Timothy David CroninAnna Maria Waaga-GasserMarina Felipe GrossiGloria Regina FrancoCarlos Alberto Tagliatiapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/52552/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINALBiomarkers and in vitro strategies for nephrotoxicity and renal disease assessment.pdfBiomarkers and in vitro strategies for nephrotoxicity and renal disease assessment.pdfapplication/pdf1027080https://repositorio.ufmg.br/bitstream/1843/52552/2/Biomarkers%20and%20in%20vitro%20strategies%20for%20nephrotoxicity%20and%20renal%20disease%20assessment.pdff15fc42c0dc61b1c70ffb51e72ece947MD521843/525522023-04-26 19:46:15.35oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2023-04-26T22:46:15Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.pt_BR.fl_str_mv |
Biomarkers and in vitro strategies for nephrotoxicity and renal disease assessment |
title |
Biomarkers and in vitro strategies for nephrotoxicity and renal disease assessment |
spellingShingle |
Biomarkers and in vitro strategies for nephrotoxicity and renal disease assessment Stellamaris Soares Acute kidney injury (AKI) Adverse outcome pathways (AOP) Chronic kidney disease (CKD) Early diagnosis Nephrotoxicity models New technologies Injúria renal aguda Insuficiência renal crônica Rotas de resultados adversos Diagnóstico precoce Nefrologia |
title_short |
Biomarkers and in vitro strategies for nephrotoxicity and renal disease assessment |
title_full |
Biomarkers and in vitro strategies for nephrotoxicity and renal disease assessment |
title_fullStr |
Biomarkers and in vitro strategies for nephrotoxicity and renal disease assessment |
title_full_unstemmed |
Biomarkers and in vitro strategies for nephrotoxicity and renal disease assessment |
title_sort |
Biomarkers and in vitro strategies for nephrotoxicity and renal disease assessment |
author |
Stellamaris Soares |
author_facet |
Stellamaris Soares Larissa Camila Ribeiro de Souza Mark Timothy David Cronin Anna Maria Waaga-Gasser Marina Felipe Grossi Gloria Regina Franco Carlos Alberto Tagliati |
author_role |
author |
author2 |
Larissa Camila Ribeiro de Souza Mark Timothy David Cronin Anna Maria Waaga-Gasser Marina Felipe Grossi Gloria Regina Franco Carlos Alberto Tagliati |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Stellamaris Soares Larissa Camila Ribeiro de Souza Mark Timothy David Cronin Anna Maria Waaga-Gasser Marina Felipe Grossi Gloria Regina Franco Carlos Alberto Tagliati |
dc.subject.por.fl_str_mv |
Acute kidney injury (AKI) Adverse outcome pathways (AOP) Chronic kidney disease (CKD) Early diagnosis Nephrotoxicity models New technologies |
topic |
Acute kidney injury (AKI) Adverse outcome pathways (AOP) Chronic kidney disease (CKD) Early diagnosis Nephrotoxicity models New technologies Injúria renal aguda Insuficiência renal crônica Rotas de resultados adversos Diagnóstico precoce Nefrologia |
dc.subject.other.pt_BR.fl_str_mv |
Injúria renal aguda Insuficiência renal crônica Rotas de resultados adversos Diagnóstico precoce Nefrologia |
description |
Acute kidney injury (AKI) is a global public health concern, impacting nearly 13.3 million patients and resulting in three million deaths per year. Chronic Kidney Disease (CKD) has increased by 135% since 1990, representing the pathology with the fastest growth rate worldwide. The annual costs of dialysis and kidney transplants range between US$35,000 and US$100,000 per patient. Despite its great impact, kidney disease has remained mostly asymptomatic for many years. AKI continues to be a major, unmet medical condition for which there are no pharmacological treatments available, while animal models are limited to provide direction for therapeutic translation into humans. Currently, serum creatinine is the standard biomarker to identify nephrotoxicity; however, it is a late stage biomarker. Hence, there is a pressing need to study in vitro biomarkers for the assessment of nephrotoxicity in order to develop new and safer drugs. Understanding of the mechanisms by which molecules produce nephrotoxicity is vital in order to both prevent adversity and treat kidney injury. In this review, we address new technologies and models that may be used to identify earlier biomarkers and pathways involved in nephrotoxicity, such as cell culture, omic approaches, bioinformatics platform, CRISPR/Cas9 genome-editing, in silico, organoids and 3D bioprinting, considering adverse outcome pathways (AOP). |
publishDate |
2020 |
dc.date.issued.fl_str_mv |
2020-05 |
dc.date.accessioned.fl_str_mv |
2023-04-26T21:36:50Z |
dc.date.available.fl_str_mv |
2023-04-26T21:36:50Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/52552 |
dc.identifier.doi.pt_BR.fl_str_mv |
https://doi.org/10.15761/NRD.1000162 |
dc.identifier.issn.pt_BR.fl_str_mv |
2399-908X |
url |
https://doi.org/10.15761/NRD.1000162 http://hdl.handle.net/1843/52552 |
identifier_str_mv |
2399-908X |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Nephrology and Renal Diseases |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.publisher.initials.fl_str_mv |
UFMG |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
FAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICAS ICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIA |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
bitstream.url.fl_str_mv |
https://repositorio.ufmg.br/bitstream/1843/52552/1/License.txt https://repositorio.ufmg.br/bitstream/1843/52552/2/Biomarkers%20and%20in%20vitro%20strategies%20for%20nephrotoxicity%20and%20renal%20disease%20assessment.pdf |
bitstream.checksum.fl_str_mv |
fa505098d172de0bc8864fc1287ffe22 f15fc42c0dc61b1c70ffb51e72ece947 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
|
_version_ |
1803589465145344000 |